謝清海斥資2,364萬元增持惠理(00806.HK)逾820萬股
惠理集團(00806.HK)聯席主席兼聯席首席投資總監謝清海近日連番增持集團共820.64萬股份,涉資2,364.05萬元。
聯交所權益披露資料顯示,謝清海於1月16日簽訂協議,向惠理集團其他董事購入共514.54萬股惠理股份,平均代價每股3元,涉資1,543.63萬元。同日謝清海以同樣價格,於交易所買入近226.1萬股,涉資近678.29萬元,完成兩項交易後其持股量增至13.73%。
隨後謝清海再於上周五(19日)在場內購入80萬股惠理股份,每股均價1.7766元,涉資近142.13萬元,持股量進一步增至13.78%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.